Aim: To evaluate treatment outcomes of locally advanced cervical cancer patients who received concurrent weekly Carboplatin or Cisplatin with radiation therapy. Methods and Materials: This study is a prospective analysis of 180 patients with cervical cancer stage IIB-IVA who were treated at our centre. Ninety patients in each arm received concurrent CTRT with weekly cisplatin or Carboplatin followed HDR-ICBT. Primary endpoint was the acute toxicities; whereas secondary endpoints were overall response rate, which includes complete and partial responses. Results: The treatment was well tolerated. Anaemia, nausea vomiting, neutropenia nephrotoxicity and bladder toxicity was more frequently occurred with weekly cisplatin and were statically significant ((P<0.05). Grade 1 thrombocytopenia was seen in more frequently with Carboplatin which was statically significant. Nephrotoxicity was limited to cisplatin arm and 13.4% & 23.3% patients developed grade 1 & grade 2 nephrotoxicity which was statically significant (P<0.001). Complete response was present in 67.8% & 66.7% patients in cisplatin and Carboplatin arm respectively which was progressed to 87.8% and 83.3% after 6 months of follow up. Disease progression was noted in 8.9% & 13.4% patients in respective arms. Conclusion: Concurrent weekly Carboplatin with radiation therapy yields high response rate with have similar toxic in locally advanced cervical cancer. Carboplatin may be feasible alternative treatment with minimal toxicities in patients who have contraindication for cisplatin.